
Feature|Articles|June 30, 2025
Most Impactful Neurology Trial Readouts From Early 2025
Author(s)Marco Meglio, Isabella Ciccone, MPH
Overviewing the major clinical trial readouts in neurology from the first half of 2025, with data that could reshape patient care.
Advertisement
Advertisement
In the first half of 2025, the neurology field has seen a wave of major clinical trial readouts that may shape the future of care across multiple disease areas. From pivotal phase 3 results in Alzheimer disease (AD) and migraines to promising data in rare neuromuscular and autoimmune disorders, the latest findings could redefine treatment possibilities and advancing precision medicine in neurology. These readouts have garnered widespread attention from clinicians and researchers alike, offering critical insights into therapeutic efficacy, safety, and trial design innovation.
Related to this article

Here's some of what is coming soon to NeurologyLive® this week.

The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.

As diabetes drugs are tested for repurposing in Alzheimer disease, the negative phase 3 EVOKE and EVOKE+ results for oral semaglutide have moved attention toward prevention and earlier, combination-based approaches.

William Roth, MD, assistant professor of neurology at the University of Chicago, discusses the role of the gut microbiome in stroke risk and recovery and emerging strategies to modify it in the acute and preventive settings.

Three randomized trials pooled in a new systematic review found that thrombectomy did not improve 90-day functional outcomes after medium or distal vessel occlusion stroke, while increasing bleeding risk.

In a phase 2a trial presented at CTAD 2026, neflamapimod kept plasma NfL stable in nonfluent variant primary progressive aphasia over 24 weeks.
Advertisement
Advertisement


